Acorda Therapeutics
Peter Henderson has a strong background in compliance and ethics, with experience working at various pharmaceutical and medical device companies. Peter most recently served as the Chief Compliance Officer at Danaher Corporation, a position they have held since December 2020. Prior to that, they held the role of Vice President - Compliance at Acorda Therapeutics, Inc. from 2016 to 2020. Peter also served as the Chief Compliance Officer at BioCryst Pharmaceuticals, Inc. from 2019 to 2020. Peter has held other compliance-related roles at Bioventus, Smith & Nephew, GE Healthcare, Roche Diagnostics, and Guidant.
Peter Henderson earned a Bachelor of Arts degree in Psychology from Northwestern University, graduating in 1993. Later, they attended Emory University School of Law where they obtained a J.D. degree, completing their legal education in 1998.
This person is not in any offices
Acorda Therapeutics
1 followers
Acorda Therapeutics is a publicly-traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders.